In Vitro Activities of MK-0826 and 16 Other Antimicrobials against Bacteroides fragilis Group Strains

AUTOR(ES)

Betriu, Carmen

FONTE

American Society for Microbiology

RESUMO

The activity of MK-0826, a new carbapenem, against 309 Bacteroides fragilis group strains was investigated and compared with that of 11 other β-lactam and 5 non-β-lactam agents. MK-0826 showed excellent activity (MICs ranged from ≤0.06 to 4 μg/ml). The new carbapenem may be useful in the treatment of mixed anaerobic infections involving B. fragilis group strains.

Documentos Relacionados

• In Vitro Activities of Tigecycline against the Bacteroides fragilis Group
• In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia
• In Vitro Activities of the Potent, Broad-Spectrum Carbapenem MK-0826 (L-749,345) against Broad-Spectrum β-Lactamase-and Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli Clinical Isolates
• In Vitro Activities of ABT-773 and Other Antimicrobials against Human Mycoplasmas
• In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical Centers